3-V Biosciences Finds $20M In Funding
Menlo Park-based 3-V Biosciences, which is developing treatments for Hepatitus C (HCV), said this week that it has closed a preferred round of funding, worht a minimum of $20M. The round came from Kleiner Perkins Caufield & Byers and New Enterprise Associates, both current investors in the firm. 3-V Biosciences is headed by Merdad V. Parsey.
posted on Friday, January 6, 2012 (Link to more information)
Related companies:
3-V Biosciences, Inc.
Related stories:
> 3-V Biosciences Finds $20M
> Xcell Biosciences Finds $12M
> Annexon Biosciences Gets $44M
> Imago Biosciences Sees $26.5M
> Calithera Biosciences Finds $35M
silicontap.com Home